nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A14510A3·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Neurology and psychiatry·Subfield: Physiology·Basis: Full text·Type: Mixed-methods study

Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology.

Pan et al.Pan, Wang, Zhang et al.·2026·Nature aging·10.1038/s43587-026-01108-z ↗

Primary claim

In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality.

Supported · two transgenic models support protective effects, but single-age cognition and small mechanistic samples limit the breadth of inference
In brief

ULK1 emerges as a credible preclinical Alzheimer’s target, but non-independent analyses and confounded human comparisons materially weaken the evidence chain.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

ULK1 (Atg1) initiates macroautophagy and mitophagy, which support neuronal growth and survival, yet how this pathway is disrupted in aging and Alzheimer's disease (AD) remains unclear. Here we report reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316). In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality. Mechanistically, ULK1 upregulation increases autophagy and PINK1-, FUNDC1- and AMBRA1-associated mitophagy; higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy. We propose that age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD and identify ULK1 as a potential therapeutic target.

Key Claims

Primary finding · Supported

In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality.

Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

two transgenic models support protective effects, but single-age cognition and small mechanistic samples limit the breadth of inference

Abstract; Results, Figs. 3–6
Quote verified
Secondary · Tentative

reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316)

small paired follow-up and confounded cohort comparisons conflict with null and positive age associations in regression analyses

Abstract; Results, Fig. 1a–b, g–h
Quote verified
Secondary · Tentative

higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy

correlated pathway readouts and one SIRT1-inhibitor experiment do not directly identify the full NAD+-mediated causal chain

Abstract; Results, Fig. 6
Quote verified
Secondary · Tentative

Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy.

pooled fields and mixed activator results support proof of concept but not robust efficacy or mammalian translation

Abstract; Results, Fig. 7
Quote verified
Secondary · Supported

higher baseline CSF ULK1 was associated with slower progression to AD

an adjusted longitudinal mixed model supports association, not a protective causal effect

Results, Fig. 1l
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad cross-system evidence chain

Human biofluids and brain tissue are connected to two AD mouse models, cultured cells, and C. elegans, providing multiple tests of the ULK1 hypothesis.

↳ Results, Figs. 1–7

#methodological rigour

Genetic testing across AD pathologies

ULK1 overexpression is evaluated in both 5xFAD amyloid and hTau.P301S tau models, with behavioral and pathological outcomes reported in each.

↳ Results, Figs. 3–6

#methodological rigour

Adjusted longitudinal progression analysis

The CDR-SB analysis models baseline CSF ULK1 by time while adjusting for demographic, clinical, Aβ, and p-tau variables.

↳ Results, Fig. 1l; Statistics and Reproducibility

Limitations

#methodological rigour

Non-independent observations drive inference

Several central cell and imaging analyses use neurons, fields, plaques, or technical repeats as inferential observations despite only three biological replicates or a small number of animals.

↳ Figs. 2j–k, 3q–s, 4e–f, 6i–l and 7a–e

#methodological rigour

Clinical comparisons retain major confounding

CU controls and AD participants differ in recruitment setting, age, sex, education, APOE status, sampling context, and biomarker laboratory, without a demonstrated adjusted disease-group ULK1 comparison.

↳ Table 1; Methods, Study Participants; Results, Fig. 1g–h

#positioning

Aging narrative conflicts with regressions

The Discussion reports a null age association in CU participants and a positive ULK1–age association in AD, yet the Abstract and later Discussion assert age-related decline and a causative role.

↳ Abstract; Discussion, paragraphs 1 and 4; Supplementary Tables 5–6

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper earns its strongest score for contribution because it links human observations to amyloid and tau mouse models, cell assays, and a worm model. Methodological breadth does not offset the use of fields, neurons, and technical repeats as inferential units in several central experiments or the absence of an adequate confounding strategy for the cross-cohort ULK1 comparison. The adjusted CDR-SB model and mouse-level behavioral outcomes remain informative, but the NAD+–SIRT1 mechanism and pharmacological claims are less secure. The Abstract and later Discussion also state age-related decline and causal disease progression more firmly than the discordant human regressions support.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.1

Contribution
3.9

The paper meaningfully extends prior ULK1 work through human biofluids and brain tissue, two AD mouse models, cell assays, and a tau-worm model. The advance is substantial, although the human and drug-development claims remain less mature than the genetic model findings.

Abstract; Results, Figs. 1–7

In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline

Methodological Rigour
1.8

The design includes multiple perturbations, blinded analyses, two mouse models, and an adjusted longitudinal CDR-SB model. Methodological Rigour is substantially reduced because central cell experiments infer from fields or technical repeats, clinical groups differ without a demonstrated adjusted disease-group comparison, and randomisation was not used.

Table 1; Figs. 2j–k, 6i–l and 7a–e; Statistics and Reproducibility

No method of randomization was used to assign samples to experimental groups.

Reporting
3.2

The human-to-model-system argument is logically organized and methods and legends are generally detailed. The Abstract nevertheless presents the age-decline and NAD+–SIRT1 causal chains more firmly than the observational and perturbational evidence supports.

Abstract; Discussion, paragraphs 1 and 8

age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD

Positioning
2.8

The Discussion engages Beclin1, AMPK–ULK1, anti-Aβ therapy, and the study's translational limitations. Its handling of the aging limitation is inconsistent because the null regression is acknowledged before later assertions of dramatic age-related decline and a causative role.

Discussion, paragraphs 1, 3–4, 6 and 8

Our data show a dramatic reduction of ULK1 in the cognitively normal older human population

Lower confidence on Methodological Rigour, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

Treatment timing, Golgi sample age, ATP tissue source, serum statistical testing and an Extended Data reference have conflicting descriptions; their effects on the reported results cannot be established.

Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated

Reference IntegrityClean

112 of 112 checkable references verified

113 references in manuscript 1 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceConceptual
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim that ULK1 overexpression reduces AD pathology and cognitive decline is demonstrated in mouse models and cells, with no human interventional validation yet.

From the paper
“our study presents a strong case for the development of ULK1 as a potential therapeutic target and disease progression biomarker for AD.”

The paper names a real-world use of its findings, namely developing ULK1 as a therapeutic target and biomarker, but does not specify which actors or settings would apply them.

Pathway

Drug developers would create ULK1-activating compounds or gene therapies that clinicians could use to slow Alzheimer's progression in patients.

Barrier

The efficacy evidence comes from transgenic mice, worms and cell assays, so human trials of ULK1 activation are needed to confirm safety and cognitive benefit in patients.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →